Using social media may impair children’s attention
Peer-Reviewed Publication
Updates every hour. Last Updated: 8-Dec-2025 00:11 ET (8-Dec-2025 05:11 GMT/UTC)
Children who spend a significant amount of time on social media tend to experience a gradual decline in their ability to concentrate. This is according to a comprehensive study from Karolinska Institutet, published in Pediatrics Open Science, where researchers followed more than 8,000 children from around age 10 through age 14.
In a special 11 December event for science journalists, the Science Press Package team will revisit the topic recognized as Science’s Breakthrough of the year in 2023: the development of GLP-1 receptor agonists to treat obesity and their efficacy in blunting obesity-associated health problems. The Mani L. Bhaumik Breakthrough of the Year Award that the American Association for the Advancement of Science, publisher of Science, gave to researchers whose work best underpinned the GLP-1 breakthrough was steered by a committee that included Dr. Katherine Saunders, obesity physician at Weill Cornell Medicine and co-founder of FlyteHealth. Dr. Saunders routinely works with media, responding to questions about how GLP-1s are prescribed as part of comprehensive cardiometabolic care. She recognizes opportunities for news stories on such topics to more accurately reflect the realities of the biology of obesity as a disease, and the science taken into account when treating patients with GLP-1s.
In this briefing, Dr. Saunders will take your questions on these topics. She will be joined by Dr. Robyn Pashby, a clinical health psychologist specializing in obesity-related behavioral science, and Dr. Tracy Zvenyach, a health policy researcher and Director of Policy Strategy at the Obesity Action Coalition. Dr. Pashby will discuss topics including the neurobehavioral links between mental health and obesity, and how GLP-1 medications influence motivation, reward processing, and treatment engagement. Dr. Tracy Zvenyach, who engages in policy advocacy and research to improve access to obesity treatments, will outline the coverage landscape, including how standard health insurance is working, and how it isn’t. She will also discuss policy implications of continued research into GLP-1s, which show a growing range of benefits.
The event will be held at 10am US ET on Thursday 11 December on Zoom. Register now to attend: https://aaas.zoom.us/webinar/register/WN_HwsyjhaBRR2RurCbJ5vhXw. Please plan to bring your questions! Note: This event is not tied to embargoed content.
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumors, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.
Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated.
The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.
Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.
Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child’s treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.
Within a year of initiation, a multidisciplinary project to improve screening and treatment for iron deficiency in pregnancy resulted in a sixfold rise in screening rates for iron deficiency in pregnant patients, a 20-fold rise in the number of intravenous (IV) iron infusions, and a significant improvement in median hemoglobin levels.